Advertisement
Mr. Weiss' presentation, which will take place on Wednesday, May 7th at9:30am EDT, will be webcast live and will be accessible from the InvestorInformation page of the Company's Website at http://investors.keryx.com. Anarchived version of the webcast will be available following the conclusion ofthe live presentation.
Advertisement
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development andcommercialization of medically important, novel pharmaceutical products forthe treatment of life-threatening diseases, including renal disease andcancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-basedcompound that has the capacity to bind to phosphate and form non-absorbablecomplexes. Zerenex is currently in Phase 2 clinical development for thetreatment of hyperphosphatemia (elevated phosphate levels) in patients withend-stage renal disease, or ESRD. The Company is also developing KRX-0401(perifosine), a novel, potentially first-in-class, oral anti-cancer agent thatmodulates Akt, a protein in the body associated with tumor survival andgrowth. KRX-0401 also modulates a number of other key signal transductionpathways, including the JNK and MAPK pathways, which are pathways associatedwith programmed cell death, cell growth, cell differentiation and cellsurvival. KRX-0401 is currently in Phase 2 clinical development for multipletumor types. The Company also has an in-licensing and acquisition programdesigned to identify and acquire additional drug candidates. Keryx isheadquartered in New York City.KERYX CONTACT: Lauren Fischer Director - Investor Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965 E-mail: [email protected]
SOURCE Keryx Biopharmaceuticals, Inc.
